High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Bone Marrow Transplantation

• Publication date

  2003-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/sj.bmt.1704089PMID 12815484
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lymphoproliferative disease after allogeneic stem cell transplantation--pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum.

  2003cited by this paper
• Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

  2002cited by this paper
• Epstein-Barr virus ( EBV ) reactivation is a frequent event after allogeneic hematopoietic stem cell transplantation and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted stem cell transplantation

  2002cited by this paper
• Chimaeric anti‐CD20 monoclonal antibody (rituximab) in post‐transplant B‐lymphoproliferative disorder following stem cell transplantation in children

  2001cited by this paper
• Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients.

  2001cited by this paper
• Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

  2001cited by this paper
• CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.

  2000cited by this paper
• Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.

  2000cited by this paper
• Diagnosis and treatment of transplant-related lymphoma.

  2000cited by this paper
• CD‐20 expression in post‐transplant lymphoproliferative disorders: Treatment with Rituximab

  2000cited by this paper
• Epstein-Barr virus infection.

  2000cited by this paper
• Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study.

  2000cited by this paper
• Epstein-barr virus-induced posttransplant lymphoproliferative disorders

  1999cited by this paper
• Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.

  1999cited by this paper
• Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting.

  1999cited by this paper
• Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome.

  1998cited by this paper
• Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation.

  1998cited by this paper
• Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience

  1998cited by this paper
• Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

  1998cited by this paper
• Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.

  1998cited by this paper
• bcl‐2 PROTEIN IS STRONGLY EXPRESSED IN POST‐TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS

  1996cited by this paper
• Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.

  1994cited by this paper
• Epstein-Barr virus.

  1991cited by this paper
• Epstein-Barr virus lymphoproliferation after bone marrow transplantation.

  1988cited by this paper
• Bone-marrow transplantation (second of two parts).

  1975cited by this paper
• CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S

  1974cited by this paper

• A model of lymphocryptovirus-associated post-transplant lymphoproliferative disorder in immunosuppressed Mauritian cynomolgus macaques

  2024cites this paper
• Pre-Emptive Use of Rituximab in Epstein–Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes

  2023cites this paper
• Epidemiology and Prognosis of PTLD After HSCT

  2021cites this paper
• Epstein–Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes

  2020cites this paper
• Post-Transplant Lymphoproliferative Disorders Arising after Allogeneic Hematopoietic Cell Transplantation: A Comprehensive Review

  2020cites this paper
• Post Transplant Lymphoproliferative Disorder

  2019cites this paper
• Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder.

  2018cites this paper
• Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein‐Barr virus‐associated post‐transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation

  2018cites this paper
• Human herpes virus antibody levels in helminth treated and placebo controlled multiple sclerosis patients

  2018cites this paper
• Overview of infections following hematopoietic cell transplantation

  2017cites this paper
• Genomic studies on the impact of host/virus interaction in EBV infection using massively parallel high throughput sequencing

  2017cites this paper
• The Role of EBV in the Pathogenesis of Diffuse Large B Cell Lymphoma.

  2015cites this paper
• Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients.

  2015cites this paper
• Hematologic neoplasms: Interpreting lung findings in chest computed tomography

  2015cites this paper
• Neoplasias hematológicas: interpretación de los hallazgos pulmonares en la tomografía computarizada torácica

  2015cites this paper
• Post-transplant lymphoproliferative disorders.

  2015cites this paper
• Identifying Predictive Factors for Posttransplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients With Epstein-Barr Virus Viremia

  2014cites this paper
• Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation

  2014cites this paper
• Epstein–Barr virus-associated posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation

  2014cites this paper
• Secondary malignancies in pediatric cancer survivors: Perspectives and review of the literature

  2014cites this paper
• Noninfectious pulmonary complications after hematopoietic stem cell transplantation: practical approach to imaging diagnosis.

  2014cites this paper
• Common non-seasonal viral infections after hematopoietic stem cell transplantation

  2013cites this paper
• The Effect of Epstein-Barr Virus Latent Membrane Protein 2 Expression on the Kinetics of Early B Cell Infection

  2013cites this paper
• hematopoietic cell transplantation Risk factors for lymphoproliferative disorders after allogeneic

  2013cites this paper
• Prognostic factors and outcome of Epstein–Barr virus DNAemia in high‐risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab

  2013cites this paper
• Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation

  2011cites this paper
• High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts

  2011cites this paper
• Epstein–Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy

  2011cites this paper
• ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation.

  2011cites this paper
• Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections

  2011cites this paper
• Graft-vs-host disease following allogeneic hematopoietic cell transplantation.

  2011cites this paper
• Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.

  2011cites this paper
• Infections in Hematopoietic Stem Cell Transplant Recipients

  2011cites this paper
• Prospective Evaluation of Epstein–Barr Virus Reactivation After Stem Cell Transplantation: Association with Monoclonal Gammopathy

  2010cites this paper
• Phase‐1 study of siplizumab in the treatment of pediatric patients with at least grade II newly diagnosed acute graft‐versus‐host disease

  2010cites this paper
• Molecular monitoring of viral infections after hematopoietic stem cell transplantation

  2010cites this paper
• Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation.

  2010cites this paper
• Epstein-Barr virus infections after allogeneic stem cell transplantation: a comparison between non-malignant and malignant hematological disorders

  2010cites this paper
• Posttransplantation lymphoproliferative disorder in children: manifestations in hematopoietic cell recipients in comparison with liver recipients.

  2010cites this paper
• A Prospective Study on Modulation of Immunosuppression for Epstein-Barr Virus Reactivation in Pediatric Patients Who Underwent Unrelated Hematopoietic Stem-Cell Transplantation

  2010influential citation
• STRATEGIES FOR MANAGEMENT OF EBV AND ADENOVIRUS INFECTIONS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

  2010cites this paper
• CELLULAR PATHWAYS LEADING TO PATTERNS OF LYTIC EPSTEIN-BARR VIRUS REACTIVATION IN IMMORTALIZED B CELL LINES

  2010cites this paper
• Pharmaceutical and cellular strategies in prophylaxis and treatment of graft-versus-host disease.

  2009cites this paper
• Primary central nervous system post‐transplant lymphoproliferative disorder presenting as cerebral hemorrhage after unrelated bone marrow transplantation

  2009cites this paper
• Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.

  2009cites this paper
• Prolonged Survival of Composite Facial Allografts in Non-Human Primates Associated With Posttransplant Lymphoproliferative Disorder

  2009cites this paper
• Viral Infections in Hematopoietic Stem Cell Transplant Recipients

  2009cites this paper
• Targeted monitoring of patients at high risk of post‐transplant lymphoproliferative disease by quantitative Epstein–Barr virus polymerase chain reaction

  2009cites this paper
• Epstein–Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients

  2008cites this paper
• Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients.

  2008cites this paper
• EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT

  2008cites this paper
• Transplantation: Posttransplant Lymphoproliferative Disorder

  2007cites this paper
• EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning

  2007cites this paper
• Retrospective evaluation of serum Epstein Barr virus DNA levels in 406 allogeneic stem cell transplant patients.

  2007cites this paper
• Reduced-intensity transplantation in the treatment of haematological malignancies: current status and future-prospects.

  2007cites this paper
• Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients.

  2007cites this paper
• CMV-, EBV-, and HHV-6-DNAemia after liver transplantation

  2007influential citation
• Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction

  2007cites this paper
• The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.

  2006cites this paper
• Chapter 31 – Non-Hodgkin's Lymphomas of Childhood

  2006cites this paper
• Clinical Characteristics and Outcomes of Posttransplant Lymphoproliferative Disorders Following Allogeneic Hematopoietic Stem Cell Transplantation in Korea

  2006cites this paper
• Monitoring of EBV-DNAemia by quantitative real-time PCR after adult liver transplantation.

  2006cites this paper
• Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation.

  2006cites this paper
• Epstein–Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation

  2006cites this paper
• Epstein–Barr virus reactivation after allogeneic stem cell transplantation without lymph node enlargement

  2005cites this paper
• Treatment of Epstein–Barr Virus-associated lymphoproliferative disorder (EBV-PTLD) and pure red cell aplasia (PRCA) with Rituximab following unrelated cord blood transplantation: A case report and literature review

  2005cites this paper
• Post-transplant lymphoproliferative disorder.

  2005cites this paper
• Immunomodulation and Safety of Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis

  2005cites this paper
• The corticosteroid‐induced inhibitory effect on NK cell function reflects down‐regulation and/or dysfunction of triggering receptors involved in natural cytotoxicity

  2004cites this paper
• Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation

  2004cites this paper
• Lymphoproliferative disease after allogeneic stem cell transplantation--pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum.

  2003cites this paper